Intertumoral Differences Dictate the Outcome of TGF-beta Blockade on the Efficacy of Viro-Immunotherapy
Christianne Groeneveldt,Jurriaan Q. Ginkel,Priscilla Kinderman,Marjolein Sluijter,Lisa Griffioen,Camilla Labrie,Diana J. M. van den Wollenberg,Rob C. Hoeben,Sjoerd H. van der Burg,Peter ten Dijke,Lukas J. A. C. Hawinkels,Thorbald van Hall,Nadine van Montfoort
DOI: https://doi.org/10.1158/2767-9764.CRC-23-0019
2023-01-01
Cancer Research Communications
Abstract:The absence of T cells in the tumor microenvironment of solid tumors is a major barrier to cancer immunotherapy efficacy. Oncolytic viruses, including reovirus type 3 Dearing (Reo), can recruit CD8(+) T cells to the tumor and thereby enhance the efficacy of immunotherapeutic strategies that depend on high T-cell density, such as CD3-bispecific antibody (bsAb) therapy. TGF-beta signaling might represent another barrier to effective Reo&CD3-bsAb therapy due to its immunoinhibitory characteristics. Here, we investigated the effect of TGF-beta blockade on the antitumor efficacy of Reo&CD3-bsAb therapy in the preclinical pancreatic KPC3 and colonMC38 tumor models, where TGF-beta signaling is active. TGF-beta blockade impaired tumor growth in both KPC3 andMC38 tumors. Furthermore, TGF-beta blockade did not affect reovirus replication in both models and significantly enhanced the Reo-induced T-cell influx in MC38 colon tumors. Reo administration decreased TGF-beta signaling in MC38 tumors but instead increased TGF-beta activity in KPC3 tumors, resulting in the accumulation of a-smooth muscle actin (aSMA(+)) fibroblasts. In KPC3 tumors, TGF-beta blockade antagonized the antitumor effect of Reo&CD3-bsAb therapy, even though T-cell influx and activity were not impaired. Moreover, genetic loss of TGF-beta signaling in CD8(+) T cells had no effect on therapeutic responses. In contrast, TGF-beta blockade significantly improved therapeutic efficacy of Reo&CD3-bsAb in mice bearing MC38 colon tumors, resulting in a 100% complete response. Further understanding of the factors that determine this inter tumor dichotomy is required before TGF-beta inhibition can be exploited as part of viroimmunotherapeutic combination strategies to improve their clinical benefit. Significance: Blockade of the pleiotropic molecule TGF-beta can both improve and impair the efficacy of viro-immunotherapy, depending on the tumor model. While TGF-beta blockade antagonized Reo&CD3-bsAb combination therapy in the KPC3 model for pancreatic cancer, it resulted in 100% complete responses in the MC38 colon model. Understanding factors underlying this contrast is required to guide therapeutic application.colonmodel